Device Trial Radar · NCT07642414
A Comprehensive Digital Care Program for Migraine Management
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Jul 9, 2026
Primary completion
Nov 6, 2026
Study completion Nov 6, 2026
Sponsor
- Lead sponsor
- Hinge Health, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 11, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the clinical effectiveness of the Enso for Migraine program, a comprehensive digital care program combining an FDA-cleared neuromodulation wearable device (Enso), personalized exercise therapy, and a dedicated care team, in reducing migraine frequency among adults with episodic or chronic migraine.
Conditions
- Migraine
- Migraine With Aura
- Migraine Without Aura
Interventions
Neuromodulation Wearable DeviceDevice
The Neuromodulation Wearable Device is an FDA-cleared (510(k)) Class II neuromodulation wearable used for acute migraine treatment. Participants use the device to treat migraine attacks as needed during the 12-week intervention phase.
Migraine Digital Care ProgramOther
A comprehensive digital care program delivered via the Hinge Health app, consisting of: (1) guided exercise therapy playlists targeting migraine prevention through structured physical activity; (2) a dedicated care team including a licensed physical therapist and health coach supporting clinical progress, adherence, and behavioral modification; (3) guided breathing exercises for relaxation and stress reduction; (4) in-app migraine trigger tracking allowing participants to log lifestyle, dietary, environmental, and hormonal factors associated with their episodes; and (5) a migraine-specific education library covering triggers, lifestyle modifications, sleep hygiene, and pain management strategies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Monthly Migraine Days (MMDs)Time frame: From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hinge Health, Inc.
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.